This Cannabis-Based Drug Is On the Verge of Making History

GW Pharmaceuticals' (NASDAQ:GWPH) lead drug Epidiolex is currently under review by the U.S. Food and Drug Administration (FDA) as a treatment for two rare types of childhood-onset epilepsy -- Dravet syndrome and Lennox-Gastaut syndrome. Epidiolex utilizes the popular cannabinoid known as cannabidiol (CBD), which is often revered for its medical benefits. Unlike tetrahydrocannabinol (THC), which is the component of the cannabis plant that gets you "high," CBD does no such thing, making it a potentially attractive option for drug developers and regulators to consider.